Introduction
============

Enterobacteriaceae are the most common pathogenic bacteria. Recently, the emergence of resistant pathogenic bacteria has caused significant problems for the clinical treatment of enterobacterial infections worldwide. There are many mechanisms leading to this resistance \[[@B1]\]. Extended-spectrum β-lactamase (ESBL)-producing pathogenic enterobacteria is a serious problem for antibiotic management because the ESBL genes are easily transferred from one organism to another via plasmids or other mobile genetic elements in combination with non-β-lactam resistance mechanisms, leading to multidrug-resistant isolates \[[@B1]\],\[[@B2]\].

Carbapenem antibiotics are a class of β-lactam antibiotics that are often used as a last resort for treating enterobacterial resistance. However, an increasing number of studies are reporting carbapenem-resistant enterobacteria \[[@B2]\]-\[[@B4]\]. Carbapenem-resistant enterobacterial infections are now clearly associated with significant morbidity and mortality. However, few studies have monitored the spread of these Enterobacteriaceae. Here, we report the spread of IMP-4-producing enterobacteria in a hospital in Chongqing, China.

Materials and methods
=====================

Study design
------------

The study period was from January 1, 2009, through December 31, 2010. All samples were collected from the Southwest Hospital, which is one of the largest teaching hospitals in Chongqing, China, with approximately 3000 beds. The bacterial isolates were identified in the clinical microbiology laboratory using standard biochemical tests and the Vitek system (BioMérieux, Hazelwood, MO). If the meropenem inhibition zone was ≤ 22 mm, an attempt was made to amplify the NDM-1 gene from the strain, and the strain was evaluated with the modified Hodge test (MHT) \[[@B5]\]. The MHT has been widely used to screen for carbapenemase activity because it directly analyzes this activity. If the sample was either MHT-positive or NDM-1-positive, the medical records and laboratory data for the associated patient were retrospectively reviewed using records available from the Southwest Hospital information system and from the microbiology laboratory. In this study, each isolate was collected from a different patient. This study was approved by the Ethics Committee of the Third Military Medical University (Approval number, KY200508).

Susceptibility testing
----------------------

Bacterial isolates were identified according to standard methods and tested against various antibiotics by the disk diffusion method; the zone diameters were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. The minimal inhibitory concentration (MIC) was evaluated for MHT-positive and NDM-1-positive strains. The MIC was determined by the agar disk dilution method in freshly prepared test medium (MH) according to the 2010 guidelines of the CLSI, and *Escherichia coli* strain ATCC 25922 was used as the control strain for the MIC testing. The resistance rate refers to the number of resistant strains divided by the total number of strains. The susceptible strains include those that are fully susceptible and those with an intermediate susceptible according to the CLSI standard.

PFGE
----

All *Klebsiella pneumoniae* isolates were analyzed by pulsed-field gel electrophoresis (PFGE) using the contour-clamped homogeneous electric field (CHEF) technique, which is similar to the method described by Shen et al. \[[@B6]\] and Gouby et al. \[[@B7]\]. The XbaI restriction enzyme was used (Takara, DaLian, China). DNA fragments were separated by electrophoresis in a 1% agarose III gel (Bio-Rad, China) with a CHEF apparatus (CHEF Mapper XA, Bio-Rad). The electrophoresis was performed at 14°C and 6 V/cm and with alternating pulses at a 120° angle in a 2- to 40-s pulse-time gradient for 24 h. The typing criteria were based on the protocol described by Shen et al. \[[@B6]\] and Tenover et al. \[[@B8]\].

Carbapenemase analysis
----------------------

Carbapenemase genes that are common in China were amplified by PCR with the primers shown in Table [1](#T1){ref-type="table"}. NDM-1-, IMI-1-, SPM-1-, IMP-1-, KPC-1-, VIM-1-, and OXA-type-positive strains were preserved in our laboratory \[[@B9]\]. The sequence analyses were performed using the BLAST program available on the National Center for Biotechnology Information server (<http://www.ncbi.nlm.nih.gov/>).

###### 

The primers used to amplify the carbapenemase genes by PCR

  **Gene**   **Primer**                          **Size (bp)**   **Reference**
  ---------- ---------------------------------- --------------- ---------------
  IMP-1 F    5'-atgagcaagttatctgtattctttat-3'         741              9
  IMP-1R     5'-ttagttgcttagttttgatggttt-3'                             
  KPC-1 F    5'-tcgccgtctagttctgctgtctt-3'            965              9
  KPC-1R     5'-ccgcgcagactcctagcctaa-3'                                
  NDM-1 F    5'-tcaccgagattgccgagcga-3'               457              9
  NDM-1R     5'-gggcagtcgcttccaacggt-3'                                 
  VIM-1 F    5'- ggtcgcatatcgcaacgcagt-3'             636              9
  VIM-1R     5'-cggcgactgagcgatttttg-3'                                 
  IMI-1 F    5'- ccattcacccatcacaac-3'                440              9
  IMI-1R     5'- ctaccgcataatcatttgc-3'                                 
  SPM-1 F    5'- ctgcttggattcatgggcgc-3'              783              1
  SPM-1R     5'- ccttttccgcgaccttgatc-3'                                
  OXA-23 F   5'- acttgctatgtggttgcttctctt-3'          797              9
  OXA-23R    5'- ttcagctgttttaatgatttcatca-3'                           
  OXA-24 F   5'- cgatcagaatgttcaagcgc-3'              559              9
  OXA-24R    5'- acgattctcccctctgcgc-3'                                 
  OXA-48 F   5'- ttggtggcatcgattatcgg-3'              744              1
  OXA-48R    5'- gagcacttcttttgtgatggc-3'                               
  OXA-51 F   5'- tccaaatcacagcgcttcaaaa-3'            639              9
  OXA-51R    5'- tgaggctgaacaacccatcca-3'                               
  OXA-58 F   5'- cgatcagaatgttcaagcgc-3'              529              1
  OXA-58R    5'- acgattctcccctctgcgc-3'                                 

Results
=======

From January 1, 2009 to December 31, 2010, 158 Enterobacteriaceae isolates (92 *K. pneumoniae*, 9 *E. coli*, and 57 *Enterobacter cloacae*) with reduced susceptibility to imipenem were identified in the hospital. Only 1 isolate of each bacterial species was selected per patient, and all of the strains were collected from patients 48 h after admission. Among the 158 Enterobacteriaceae, the Hodge test was positive for 26 strains (20 *K. pneumoniae*, 4 *E. coli*, and 2 *E. cloacae*), and no strain was NDM-1-positive. The features of these isolates and the patients are presented in Table [2](#T2){ref-type="table"}. Among twenty-six clinical strains, eighteen isolates were IMP-4 positive, and one was KPC-2 positive. Seventeen strains were from sputum, and sixteen strains were from pediatrics. All the strains of group A PFGE genotype were from pediatrics.

###### 

**Features of the*Enterobacteriaceae*clinical isolates**

        **Collection date**   **Strain**   **Gender**    **Age**      **Specimen**     **Hospital days**              **Ward**                       **Diagnosis**             **PFGE genotype**   **Carbapenemase gene**   **IMP-MIC**   **MEM-MIC**
  ---- --------------------- ------------ ------------ ------------ ----------------- ------------------- -------------------------------- ---------------------------------- ------------------- ------------------------ ------------- -------------
   1         2009-9-28           Kpn          Male       31 days         Sputum               11                     Pediatrics                     Acute pneumonia                    A                   IMP-4                 2             1
   2         2009-10-7           Kpn         Female       2 days          Blood                7                     Pediatrics                    Neonatal pneumonia                  A                   IMP-4                 4             2
   3        2009-12-19           Kpn         Female      10 days         Sputum                6                     Pediatrics                    Neonatal pneumonia                  A                   IMP-4                \<1           \<1
   4        2009-12-26           Kpn          Male       56 years    Abdominal fluid          31              Hepatobiliary department            Abdominal infection                  C                     \-                  8             8
   5         2010-4-3            Kpn          Male       30 days         Sputum                8                     Pediatrics                     Acute pneumonia                    E                   IMP-4                64            128
   6         2010-4-10           Eco         Female      57 years    Abdominal fluid          21                        ICU                    Severe acute pancreatitis              \-                   IMP-4                 4             2
   7         2010-5-15           Ecl          Male       15 days         Sputum               22                     Pediatrics                    Neonatal pneumonia                 \-                   IMP-4                 4             8
   8         2010-5-24           Kpn          Male      58 minutes       Sputum               11                     Pediatrics                    Neonatal pneumonia                  A                   IMP-4                 4             4
   9         2010-5-26           Kpn          Male      38 minutes       Sputum               11                     Pediatrics                    Neonatal pneumonia                  E                   IMP-4                16            16
   10        2010-5-29           Kpn          Male       2 months        Sputum               21                     Pediatrics                     Acute pneumonia                    B                   IMP-4                128           64
   11        2010-5-29           Kpn          Male       6 hours         Sputum               12                     Pediatrics                    Neonatal pneumonia                  A                   IMP-4                 4             4
   12        2010-6-3            Kpn         Female     50 minutes       Sputum               88                     Pediatrics                    Neonatal pneumonia                  A                     \-                  4             2
   13        2010-6-29           Kpn         Female      19 days         Sputum               12                     Pediatrics                    Neonatal pneumonia                  A                   IMP-4                \<1           \<1
   14        2010-6-29           Eco          Male       56 years        Ascites              37            Department of hepatobiliary     Carcinoma of the pancreatic head          \-                   IMP-4                \<1           \<1
   15        2010-7-3            Kpn          Male       20 years        Sputum               49                        ICU                    Open craniocerebral injury              E                     \-                  4             4
   16        2010-7-3            Eco          Male       79 years        Sputum                6           Department of gastroenterology        Chordapsus, pneumonia                \-                     \-                 \<1           \<1
   17        2010-7-17           Kpn          Male        1 hour         Sputum                9                     Pediatrics                    Neonatal pneumonia                  A                   IMP-4                 1            \<1
   18        2010-7-21           Kpn          Male        1 hour         Sputum                7                     Pediatrics                    Neonatal pneumonia                  A                     \-                  2             1
   19        2010-7-21           Eco         Female      44 years         Blood               46            Department of hepatobiliary       Congenital choledochus cyst             \-                     \-                  2             1
   20        2010-7-23           Kpn         Female      16 days         Sputum               10                     Pediatrics                    Neonatal pneumonia                  E                   IMP-4                32            16
   21        2010-7-23           Kpn          Male        1 hour         Sputum               18                     Pediatrics                    Neonatal pneumonia                  C                   IMP-4                32            32
   22        2010-7-23           Kpn          Male       60 years         Blood               46                        ICU                        Multiple injuries                   E                   IMP-4                 8             8
   23       2010-10-11           Kpn         Female      26 days         Sputum               12                     Pediatrics                    Neonatal pneumonia                  A                   IMP-4                 2             2
   24       2010-10-17           Ecl          Male       54 years         Wound               48                        ICU                        Penetrating wound                  \-                     \-                  1            \<1
   25       2010-10-20           Kpn         Female      69 years         Wound               17              Department of neurology                  Pneumonia                       D                   KPC-2                16             8
   26       2010-10-20           Kpn         Female      64 years         Wound               34                        Burn                              Burn                         B                   IMP-4                 2             2

The results of MIC range, MIC~50~ and MIC~90~ analyses are presented in Table [3](#T3){ref-type="table"}. We used previously described PCR reactions to screen for carbapenem-hydrolyzing β-lactamase genes. The PCR reactions for the IMP-4 and KPC-2 genes were positive \[[@B9]\]. The major epidemic pattern A consisted of ten IMP-4-positive isolates from the Department of Pediatrics. However, the only one KPC-2-positive strain was collected from the Department of Neurology.

###### 

**MIC range, MIC**~**50**~**and MIC**~**90**~**for antibiotics tested against Enterobacteriaceae**

  **Antimicrobial agent**   **MIC range (μg/ml)**   **MIC**~**50**~**(μg/ml)**   **MIC**~**90**~**(μg/ml)**
  ------------------------- ----------------------- ---------------------------- ----------------------------
  Imipenem                  1 \< − 128              4                            16
  Meropenem                 1 \< − 64               2                            16
  Ceftazidim                1 \< − \> 512           512                          \> 512
  Ceftriaxone               1 \< − \> 512           \> 512                       \> 512
  Piperacillin/tazobactam   1 \< − \> 512           128                          512
  Piperacillin              1 − \> 512              \> 512                       \> 512
  Ciprofloxacin             1 \< − 64               4                            32
  Levofloxacin              1 \< −128               8                            32
  Gentamicin                1 \< − \>512            8                            64
  Tobramycin                1 \< − \>512            4                            64

XbaI pulsed-field gel electrophoresis was then used to study the genetic relatedness of the 20 *K. pneumoniae* isolates. The results are presented in Figure [1](#F1){ref-type="fig"}, and they suggest nosocomial transmission.

![**PFGE analysis of genomic DNA from isolates of*K. pneumoniae.***](s12941-014-0042-4-1){#F1}

Discussion
==========

In the present study, we analyzed the carbapenemase genes and assessed the spread of IMP-4-positive enterobacteria in a hospital in Chongqing, China. IMP-4 is a common MBL and was first reported in *Acinetobacter baumannii* in Hong Kong, China; it subsequently spread throughout the world, particularly to mainland China and Australia \[[@B10]\],\[[@B11]\]. IMP-4 has been reported in enterobacteria in China \[[@B12]\] but has not been found in Southwestern China. Previously, we found that the IMP-4 gene existed in *A. baumannii* (data were not shown) and *Pseudomonas aeruginosa*\[[@B9]\]. Since 2007, we have detected the carbapenemase genes in enterobacteria. In 2009, we found the first carbapenemase gene, IMP-4, which we subsequently showed to be spreading among enterobacteria. However, IMP-8 has been reported in Chongqing despite the presence of IMP-4 \[[@B13]\]. These results suggested that IMP-4 may be transferred to enterobacteria from other bacteria in our hospital. After the first IMP-4-positive *K. pneumoniae* strain was found in the Pediatrics Unit, 18 IMP-4-positive enterobacteria were identified, including one *E. cloacae and two E. coli* strains. KPC-2 is common in the coastal cities of China, such as Hangzhou and Shanghai \[[@B14]\],\[[@B15]\]. Only one KPC-2-positive strain was found among the clinical isolates, and it was reported in The First Affiliated Hospital of Chongqing Medical University, Chongqing \[[@B13]\]. Since then, we have not found another KPC-2-positive strain. Thus, the KPC-2-positive strain may have been present in the patient prior to hospitalization and not acquired from a hospital ward.

For seven MHT-positive strains, no carbapenemase gene was amplified. The MHT has negative and positive likelihood rates, and the positive likelihood rate in our experiment is higher than that in a previous report \[[@B16]\]. Here, we only tested for the commonly appearing carbapenemase genes in China, so it is possible that these seven strains have other resistance genes. The MHT- and IMP-4-positive strains exhibited low-level resistance and even susceptibility to carbapenems in our study, and Nordmann reported similar results \[[@B2]\]. Thus, the highly resistant strains carrying IMP-4 must have additional mechanisms for carbapenem resistance, such as outer-membrane permeability defects, other resistance genes, or target alteration. Therefore, to treat carbapenemase-positive strains, carbapenem antibiotics, although not the preferred choice, may be the only choice.

The PFGE revealed genetic diversity among the 20 *K. pneumoniae* isolates, which belonged to five PFGE types. Ten strains of *K. pneumoniae* shared the same PFGE type. The phenomenon of the same clones spreading within the same wards or throughout different wards during the same period was observed. The same clones had similar resistance results but slightly different MIC results, suggesting that some features of the bacteria had changed as they spread and replicated or that these bacteria could easily exchange mobile genetic elements. These findings indicated that the decreased susceptibility to carbapenems in *K. pneumoniae* may arise by the stepwise accumulation of multiple carbapenem resistance determinants in different clones. These results suggest that this type of infection can be classified as a hospital-derived infection. Therefore, controlling hospital infections is a method for reducing the accumulation of bacteria resistance determinants.

The average hospital stay of the patients with these isolates was 23.1 days, while the average hospital stay of all patients in our hospital was 9.8 days. Long-term acute care hospitals (LTACHs) may play a particularly important role in the spread of KPC-producing Enterobacteriaceae, particularly among neonates or patients with a serious illness who have a reduced immune system functional capacity and who are undergoing invasive examinations or treatments. Our results support the conclusions reported by Endimiani \[[@B17]\]. Thus, for patients with a high risk of infection, reinforcement of infection control measures based on the guidance for carbapenemase-producing Enterobacteriaceae prevention \[[@B17]\] with early warning is particularly critical and should include promotion of hand hygiene. In addition, the immediate initiation of contact precautions is necessary, which can lead to a considerable reduction in hospital-acquired carbapenemase producers. Our findings also suggest that a significant containment of carbapenem-resistant *K. pneumoniae* strains from the environment is possible with the implementation of a comprehensive infection control intervention program that includes active surveillance, carrier isolation/cohorting, and a dedicated staff to treat individuals who become infected. The advent of these tests has enabled the early detection of clonal strains that are likely to be introduced into our hospital, especially from patients with previous hospitalizations. In the future, we will analyze more diverse strains and resistant genes. After infection control measures are reinforced, we will conduct additional infection control studies to test the effects of reinforcing infection control measures.

Taken together, these findings reveal the process involved in the recent spread of IMP-4 in our hospital. Carbapenem-resistant enterobacteria have become a significant concern in our hospital. The presence of carbapenemases, such as KPC-2 and IMP-4, may have played a significant role in the development of these resistant strains. Cooperation among the clinical microbiology laboratory, the infection control team, and the medical and nursing staff is vital for the design and implementation of appropriate infection control measures for carbapenemase-producing pathogens. The use of active surveillance as part of this multifactorial intervention may also aid in decreasing the secondary transmission rates of imported genes. Other interventions, such as shortening the average length of hospital stays, may further augment these infection control actions. Examining whether our interventions change the prevalence of other, less common, multidrug-resistant pathogens will also be of interest.

Competing interests
===================

The authors declare that they have no competing interests.

Authors' contributions
======================

SC carried out the protocol design and drafted this manuscript. WF carried out the collection and analysis of data for this study, and revised the content. JC carried out the collection of data, the analysis and interpretation of these data. WL, NH and QW participated in the collection of data for this study. FS and PX carried out the protocol design, collection of data, the analysis and interpretation of these data, and drafted and revised the content of this manuscript. All authors read and approved the final manuscript.
